Description
Description
Glataxone 20mg Injection contains an active component called Glatiramer acetate. It is a medication used to treat multiple sclerosis (MS). Multiple sclerosis (MS) is a chronic, often disabling disease that affects the central nervous system (CNS), which includes the brain and spinal cord. Research suggests that this medication may have neuroprotective properties, helping to protect nerve cells from damage and potentially preserving neurological function in MS.
Glataxone 20mg Injection should not be used in individuals with known hypersensitivity to it or any of its components. The kidneys primarily excrete this medication, so individuals with severe renal impairment may require close monitoring or dose adjustments if they are prescribed this medication. There is limited data on the specific use of this medication in older adults. However, it is generally considered safe for use in this population, with dosing adjustments possibly necessary based on individual health status and renal function. Glataxone 20mg Injection has not been extensively studied in children, and its safety and efficacy in pediatric populations have yet to be established.
Date of Approval
In 2015, the FDA approved the first generic version of glatiramer acetate, Glatopa, as a fully substitutable injectable aqueous solution (AP)-rated generic for all approved indications of the Copaxone 20 mg/mL dosage form.
Mechanism of Action of Glatiramer Acetate
Glatiramer acetate (GA) is an immunomodulatory drug that reduces the number of relapses in multiple sclerosis (MS).
Uses of Glatiramer Acetate
Treatment of multiple sclerosis (MS)
Glatiramer Acetate Dosage available
Glataxone 20mg Injection is primarily administered via subcutaneous injection. The dosage of this medication can vary depending on the specific formulation and the individual’s condition.
